Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.47 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | PPIA | P62937 | 1/20 | 0.41 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL810599 | 0.92 | ALDH1A1 (0.58) | ALDH1A1CYP3A4GPR35CXCR2TSHR | |
| SCHEMBL9867829 | 0.85 | ALDH1A1 (0.53) | ALDH1A1CYP3A4GPR35TSHRMAPK1 | |
| SCHEMBL68172 | 0.84 | ALDH1A1 (0.71) | ALDH1A1CYP3A4GPR35CXCR2TSHR | |
| SCHEMBL4368022 | 0.84 | GPR35 (0.54) | ALDH1A1CYP3A4GPR35TSHRMAPK1 | |
| SCHEMBL31592017 | 0.84 | TSHR (0.52) | ALDH1A1CYP3A4GPR35TSHRMAPK1 | |
| SCHEMBL3633645 | 0.84 | TSHR (0.52) | ALDH1A1CYP3A4GPR35TSHRMAPK1 | |
| SCHEMBL2565885 | 0.82 | ALDH1A1 (0.69) | ALDH1A1CYP3A4GPR35CXCR2TSHR | |
| SCHEMBL10266188 | 0.82 | GPR35 (0.52) | ALDH1A1CYP3A4GPR35TSHRMAPK1 | |
| SCHEMBL11555308 | 0.82 | ALDH1A1 (0.69) | ALDH1A1CYP3A4GPR35CXCR2TSHR | |
| SCHEMBL1626324 | 0.82 | TSHR (0.50) | ALDH1A1CYP3A4GPR35TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0342532-B1 | PROCESS FOR THE PREPARATION OF 4-CHLORO-2-METHYL-5-NITRO-PHENOL | Wella Aktiengesellschaft (DE) | 1993-01-07 | — | — | EP | claimed |
| US-4960955-A | Process for making 4-chloro-2-methyl-5-nitro-phenol | WELLA AKTIENGESELLSCHAFT (DE) | 1990-10-02 | — | — | US | claimed |
| EP-0211238-B1 | AMINOPHENOLS AND THEIR USE AS OXIDATION HAIR DYEING AGENTS | Henkel Kommanditgesellschaft auf Aktien (DE) | 1990-04-04 | — | — | EP | claimed |
| EP-0342532-A1 | Process for the preparation of 4-chloro-2-methyl-5-nitro-phenol | Wella Aktiengesellschaft (DE) | 1989-11-23 | — | — | EP | claimed |
| EP-0211238-A1 | Aminophenols and their use as oxidation hair dyeing agents | Henkel Kommanditgesellschaft auf Aktien (DE) | 1987-02-25 | — | — | EP | claimed |
| US-20150041734-A1 | POLARIZING FILM, IMAGE DISPLAY, AND METHOD FOR PRODUCING POLARIZING FILM | NITTO DENKO CORPORATION (JP) | 2015-02-12 | — | — | US | disclosed |
| CN-101233131-B | Macrocyclic inhibitors of hepatitis c virus | TIBOTEC PHARM LTD | 2011-06-08 | — | — | CN | disclosed |
| US-7659245-B2 | Macrocylic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD (IE) | 2010-02-09 | — | — | US | disclosed |
| US-7659245-B2 | Macrocylic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD (IE) | 2010-02-09 | — | — | US | disclosed |
| US-7659245-B2 | Macrocylic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD (IE) | 2010-02-09 | — | — | US | disclosed |
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| EP-0211238-B1 | AMINOPHENOLS AND THEIR USE AS OXIDATION HAIR DYEING AGENTS | Henkel Kommanditgesellschaft auf Aktien (DE) | 1990-04-04 | — | — | EP | disclosed |
| EP-0342532-A1 | Process for the preparation of 4-chloro-2-methyl-5-nitro-phenol | Wella Aktiengesellschaft (DE) | 1989-11-23 | — | — | EP | disclosed |
| EP-0342532-A1 | Process for the preparation of 4-chloro-2-methyl-5-nitro-phenol | Wella Aktiengesellschaft (DE) | 1989-11-23 | — | — | EP | disclosed |
| EP-0342532-A1 | Process for the preparation of 4-chloro-2-methyl-5-nitro-phenol | Wella Aktiengesellschaft (DE) | 1989-11-23 | — | — | EP | disclosed |
| US-4863942-A | Novel resorcinol ethers and anti-inflammatory and anti-allergic use thereof | CIBA-GEIGY CORPORATION (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0165897-B1 | RESORCIN ETHERS | CIBA-GEIGY AG (CH) | 1989-03-15 | — | — | EP | disclosed |
| EP-0211238-A1 | Aminophenols and their use as oxidation hair dyeing agents | Henkel Kommanditgesellschaft auf Aktien (DE) | 1987-02-25 | — | — | EP | disclosed |
| EP-0165897-A2 | Resorcin ethers | CIBA-GEIGY AG (CH) | 1985-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150041734-A1 | POLARIZING FILM, IMAGE DISPLAY, AND METHOD FOR PRODUCING POLARIZING FILM | PYM1, H1-0, CHRM1 | ALDH1A1 2833/4885CYP3A4 1349/4885GPR35 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.